|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
64,210,000 |
Market
Cap: |
N/A |
Last
Volume: |
2,748 |
Avg
Vol: |
1,546,173 |
52
Week Range: |
$0.000001 - $0.238 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Infinity Pharmaceuticals is a clinical-stage biopharmaceutical company. Co. is focused on advancing eganelisib (IPI-549), an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma. The preclinical findings indicate that eganelisib may have the potential to treat various solid tumors and represents an additive or synergistic approach to restoring anti-tumor immunity in combination with other immunotherapies such as checkpoint inhibitors. Further, preclinical studies showed that eganelisib inhibits the regrowth of tumors that can occur following treatment with chemotherapy.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
410,196 |
425,190 |
Total Sell Value |
$0 |
$0 |
$28,714 |
$38,646 |
Total People Sold |
0 |
0 |
1 |
2 |
Total Sell Transactions |
0 |
0 |
1 |
2 |
End Date |
2023-12-28 |
2023-09-26 |
2023-03-28 |
2022-03-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Perkins Adelene Q |
Director |
|
2023-09-12 |
4 |
AS |
$0.07 |
$28,714 |
D/D |
(410,196) |
1,175,291 |
|
-100% |
|
Perkins Adelene Q |
Director |
|
2023-09-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
768,133 |
1,585,487 |
|
- |
|
Peluso Stephane |
Chief Scientific Officer |
|
2022-08-02 |
4 |
S |
$0.66 |
$9,932 |
D/D |
(14,994) |
37,052 |
|
23% |
|
Peluso Stephane |
Chief Scientific Officer |
|
2022-08-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
50,000 |
52,046 |
|
- |
|
Evnin Anthony B |
|
|
2022-06-16 |
4 |
A |
$0.68 |
$31,491 |
D/D |
46,378 |
215,403 |
|
- |
|
Schwartz Brian |
|
|
2022-06-16 |
4 |
A |
$0.68 |
$20,994 |
D/D |
30,919 |
30,919 |
|
- |
|
Peluso Stephane |
Chief Scientific Officer |
|
2021-08-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,046 |
|
-21% |
|
Evnin Anthony B |
|
|
2021-06-10 |
4 |
A |
$3.43 |
$10,499 |
D/D |
3,061 |
169,025 |
|
- |
|
Beier David W |
|
|
2021-06-10 |
4 |
A |
$3.43 |
$10,499 |
D/D |
3,061 |
8,775 |
|
- |
|
Selby Norman C |
|
|
2021-05-14 |
4 |
OE |
$0.92 |
$4,600 |
D/D |
5,000 |
15,000 |
|
- |
|
Lampert Mark N |
10% Owner |
|
2021-02-11 |
4 |
S |
$5.37 |
$12,133,492 |
D/D |
(2,260,085) |
534,847 |
|
30% |
|
Lampert Mark N |
10% Owner |
|
2021-01-22 |
4 |
S |
$4.14 |
$24,205,855 |
D/D |
(5,848,520) |
686,974 |
|
22% |
|
Evnin Anthony B |
Director |
|
2020-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
22,826 |
165,964 |
|
- |
|
Kutok Jeffery |
Chief Scientific Officer |
|
2020-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
64,219 |
77,376 |
|
- |
|
Bloch Lawrence E |
President |
|
2020-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
83,157 |
745,094 |
|
- |
|
Perkins Adelene Q |
Chief Executive Officer |
|
2020-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
155,134 |
793,190 |
|
- |
|
Tasker Seth A |
Chief Business Officer |
|
2020-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
53,538 |
101,364 |
|
- |
|
Agresta Samuel |
Director |
|
2019-10-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
10,593 |
|
- |
|
Evnin Anthony B |
Director |
|
2019-06-13 |
4 |
A |
$1.60 |
$21,000 |
D/D |
13,125 |
143,138 |
|
- |
|
Berkowitz Jeffrey |
Director |
|
2019-06-13 |
4 |
A |
$1.60 |
$42,000 |
D/D |
26,250 |
85,238 |
|
- |
|
Lampert Mark N |
10% Owner |
|
2018-12-13 |
4 |
B |
$1.20 |
$209,913 |
D/D |
175,000 |
6,631,136 |
2.45 |
- |
|
Lampert Mark N |
10% Owner |
|
2018-11-28 |
4 |
B |
$1.30 |
$130,000 |
D/D |
100,000 |
6,510,597 |
2.45 |
- |
|
Lampert Mark N |
10% Owner |
|
2018-11-21 |
4 |
B |
$1.35 |
$6,345 |
D/D |
4,700 |
1,254,993 |
2.37 |
- |
|
Lampert Mark N |
10% Owner |
|
2018-11-19 |
4 |
B |
$1.35 |
$2,005,076 |
D/D |
1,465,126 |
1,254,412 |
2.45 |
- |
|
Lampert Mark N |
10% Owner |
|
2018-11-15 |
4 |
B |
$1.35 |
$123,490 |
D/D |
91,474 |
5,815,887 |
2.45 |
- |
|
227 Records found
|
|
Page 1 of 10 |
|
|